The Synergistic Effect of Recombinant Human Endostatin (YH-16) Combined with Oxaliplatin on Human Colorectal Carcinoma

Abstract

This study was designed to investigate the effect of recombinant human endostatin (YH-16) combined with oxaliplatin (L-OHP) on the growth of orthotopicallyimplanted human colorectal carcinoma in nude mice. Tumour volumes and weights were measured after therapy. Tumour cell morphology was observed by light and electron microscopy. Apoptosis was detected using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labelling (TUNEL) assay, and vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) were determined by immunohisto-chemical staining. Tumour volumes in all treatment groups were significantly reduced compared with controls. YH-16 and L-OHP either alone or in combination caused tumour cell apoptosis, except in the YH-16 low-dose group. MVD was strongly inhibited in the treatment groups compared with the controls, although only YH-16 combined with L-OHP or L-OHP alone decreased VEGF expression. No obvious change in side-effects occurred. In conclusion, YH-16 combined with L-OHP inhibited growth and induced apoptosis in orthotopically-transplanted human colorectal carcinoma in nude mice without increasing side-effects.

Keywords

Colorectal carcinoma Nude mouse model Recombinant human endostatin Oxaliplatin Anti-angiogenic drugs Apoptosis Synergistic effect

References

Boyle

Langman

: ABC of colorectal cancer: Epidemiology. BMJ 2000; 321: 805–808.

Tang

X-Y

Zhu

Y-Q

Tao

W-H

: Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 2007; 83: 338–343.

O'Reilly

Boehm

Shing

: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285.

Abdollahi

Hahnfeldt

Maercker

: Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649–663.

Jin

Bookstein

Wills

: Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther 2001; 8: 982–989.

Folkman

: Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594–607.

Boehm

Folkman

Browder

: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407.

Brideau

Makinen

Elamaa

: Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 2007; 67: 11528–11535.

Sun

Wang

Liu

: Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005; 23 (suppl): 7138.

10.

Simpson

Dunn

Curran

: Oxaliplatin: A review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 2003; 63: 2127–2156.

11.

Chou

Talalay

: Quantitative analysis of dose effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.

12.

Chou

Motzer

Tong

: Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517–1524.

13.

Weidner

: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36: 169–180.

14.

Weidner

: Tumour vascularity and proliferation: Clear evidence of a close relationship. J Pathol 1999; 189: 297–299.

15.

Mattern

Koomagi

Volm

: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73: 931–934.

16.

Greenlee

Hill-Harmon

Murray

: Cancer statistics. CA Cancer J Clin 2001; 51: 15–36.

17.

de Geus-Oei

Vriens

van Laarhoven

: Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: A systematic review. J Nucl Med 2009; 50 (suppl 1): 43S–54S.

18.

Gebbia

Verderame

Ferraù

: Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. Ann Oncol 2006; 17 (suppl 7): vii60–vii65.

19.

Weinstat-Saslow

Steeg

: Angiogenesis and colonization in the tumor metastatic process: Basic and applied advances. FASEB J 1994; 8: 401–407.

20.

Kerbel

Folkman

: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727–739.

21.

Folkman

: Endogenous angiogenesis inhibitors. APMIS 2004; 112: 496–507.

22.

Dutour

Monteil

Paraf

: Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: Study in a human-like rat orthotopic tumor. Mol Ther 2005; 11: 311–319.

23.

Yokoo

Masuda

Yonezawa

: Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos 2008; 36: 2299–2306.

24.

Droz

Muracciole

Mottet

: Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 2003; 14: 1291–1298.

25.

Allen

Johnston

: Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005; 23: 4545–4552.

26.

Qin

Zhao

: Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World J Gastroenterol 2009; 15: 871–876.

27.

Black

Agner

: Tumour regression after endostatin therapy. Nature 1998; 391: 450.

28.

Boehle

Kurdow

Schulze

: Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer 2001; 94: 420–428.

29.

Drixler

Borei

Rinkes IH

Ritchie

: Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000; 60: 1761–1765.

30.

Chen

Wang

: Initiator caspases in apoptosis signaling pathways. Apoptosis 2002; 7: 313–319.

31.

Green

: Apoptotic pathways: Ten minutes to dead. Cell 2005; 121: 671–674.

32.

Fisher

: Apoptosis in cancer therapy: Crossing the threshold. Cell 1994; 78: 539–542.

33.

Collins

Rivas

A Lopez

: The control of apoptosis in mammalian cells. Trends Biochem Sci 1993; 18: 307–309.

34.

Darzynkiewicz

: Apoptosis in antitumor strategies: Modulation of cell cycle or differentiation. J Cell Biochem 1995; 58: 151–159.

35.

Yao

Zhao

Sun

: Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer. Tohoku J Exp Med 2008; 215: 267–278.

36.

Dhanabal

Ramchandran

Waterman

: Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721–11726.

37.

Semenza

: Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003; 54: 17–28.

38.

Dkhissi

Soria

: Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 2003; 14: 997–1008.

39.

French

: Dysmenorrhea. Am Fam Physician 2005; 71: 285–291.

40.

Lee

Shiau

: Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 2004; 6: 1382–1393.

41.

Yeh

Chuang

: The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol 2005; 69: 307–318.

42.

Yamanaka

Tanaka

: Gene therapy of brain tumor with endostatin. Drugs Today (Barc) 2004; 40: 931–934.

43.

Rehn

Veikkola

Kukk-Valdre

: Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001; 98: 1024–1029.

44.

Hellberg

Wallin

Eriksson

: Cisplatin and oxaliplatin toxicity: Importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009; 101: 37–47.

45.

Carmeliet

Jain

: Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–257.

46.

te Velde

Vogten

Gebbink

: Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 2002; 89: 1302–1309.